Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
First Quarter 2024
- Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to
SEK 6,256 M (5,239) - Haematology revenue increased 46 per cent at CER to
SEK 4,075 M (2,815), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® ofSEK 756 M (475), sales of Vonjo® ofSEK 320 M (—), and sales of Aspaveli®/Empaveli® ofSEK 240 M (95) - Immunology revenue decreased 11 per cent at CER to
SEK 1,908 M (2,151), mainly reflecting a significant drop in Synagis® sales toSEK 520 M (1,398), partly compensated by strong sales of Gamifant® ofSEK 438 M (219), and royalty on Beyfortus™ ofSEK 318 M (—) - Revenue from medicines in the strategic portfolio more than doubled in the quarter, to
SEK 2,193 M (794), driving the majority of the growth. The strategic portfolio grew by 177 per cent at CER and helped to further transform the company - The adjusted EBITA margin1,2 was 37 per
cent (40) , excluding items affecting comparability (IAC)2. EBITA wasSEK 2,177 M (2,121), corresponding to a margin of 35 percent (40) . EBIT wasSEK 1,313 M (1,495) - Earnings per share (EPS) before dilution was
SEK 2.35 (3.44)3. Adjusted EPS before dilution1 wasSEK 2.70 (3.44)3. Cash flow from operating activities wasSEK 2,256 M (1,983)
Outlook 2024 - unchanged
- Revenue is anticipated to grow by a high single-digit percentage at CER
- The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue
1. Alternative Performance Measures (APMs). |
2. Items affecting comparability (IAC). |
3. Comparatives have been adjusted to consider the bonus issue element in the rights issue carried out in 2023. |
The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding
Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please use the following dial-in details:
For other countries, please find the details here.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Sobi Q1 2024 report. Strong sales reflecting the strength of the portfolio |
View original content:https://www.prnewswire.com/news-releases/sobi-q1-2024-report-strong-sales-reflecting-the-strength-of-the-portfolio-302127101.html
SOURCE